Maravai LifeSciences Holdings, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $51.4 million (+8.5% year over year) and diluted EPS of -$0.08. It usually reports 37–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
51
+8.5%
|
-12
+68.6%
|
-0.08
+70.4%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
66
+40.5%
|
-4
+87.5%
|
-0.02
+90.5%
|
|
Feb 25, 2026
56 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
50
-11.8%
|
-36
-37.7%
|
-0.25
-34.6%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
42
-39.7%
|
-26
+73.7%
|
-0.18
+73.5%
|
|
Aug 11, 2025
42 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
47
-31.7%
|
-40
-304.4%
|
-0.27
-285.7%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
47
-27.0%
|
-30
-147.9%
|
-0.21
-133.3%
|
|
Jan 8, 2025
8 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
57
-23.7%
|
-26
+75.6%
|
-0.18
+77.2%
|
|
Nov 7, 2024
38 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1823239
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.